Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
AbbVie said its neuroscience franchise grew in 1H 2026, with sales of $6.1B, up 21.8% year over year on an operational basis. Vraylar led at $1.98B (+18.6%), with Ubrelvy $731M (+26.4%), Qulipta $646M (+39.2%), Botox $2.05B (+13.2%), and Vyalev $457M. AbbVie raised 2026 neuroscience guidance to about $12.7B (+$100M) and overall revenue to about $67.6B (+$300M). It expects an FDA decision on tavapadon for PD in 3Q 2026.
How this was made
The 30-second read
Why it matters
For traders, the key decision points are the raised 2026 neuroscience revenue forecast and the stated Q3 2026 FDA decision timeline, which can drive estimate revisions and option-implied volatility into 2H 2026.
Market read
Concrete guidance increase and a specific regulatory milestone provide tradable catalysts for ABBV tied to 2H 2026 neuroscience growth.
What to watch
The article does not quantify probability of approval, competitive dynamics, or payer/access constraints that could affect peak sales versus the implied $5B+ scenario.
Background
The piece frames AbbVie’s neuroscience franchise performance in 1H 2026 and ties it to a higher 2026 outlook and a potential new PD entrant (tavapadon).
Ticker impact
AbbVie raised its 2026 neuroscience revenue outlook to about $12.7B and expects an FDA decision on tavapadon in Q3 2026.
Moderately positive bias, with upside skew into Q3 2026 as tavapadon approval odds and launch timing get repriced.
The article provides concrete, time-bound catalysts: higher full-year neuroscience revenue forecast and a stated Q3 2026 FDA decision window for tavapadon, alongside continued strong sales momentum in Vraylar, Ubrelvy, Qulipta, Botox Therapeutic, and Vyalev.
Market effects
Reinforces demand strength in CNS/neurology franchises and may support sentiment for large-cap pharma with neuroscience pipelines.
Primarily US large-cap pharma sentiment; limited direct regional spillover described.
US FDA decision timing is globally relevant for PD treatment competition and launch expectations.
Counterpoint
Raised guidance may already be partially anticipated; tavapadon approval risk could cap near-term upside if odds are not improving.
Key entities
- companyAbbVie
Neuroscience franchise growth, raised 2026 neuroscience outlook, and planned FDA decision for tavapadon in Q3 2026.
- drugtavapadon
Once-daily oral PD therapy with an expected FDA decision in Q3 2026, potentially expanding AbbVie’s PD franchise.
